Through the Foundry, we de-risk the technology and the market before we build
We run low-capital experiments to pressure-test the IP. Expert reviews, targeted experiments, and real-world validation ensures we only build around what works, not just what looks promising.
We engage potential acquirers early to align on unmet needs. This helps us shape companies with real buy-side interest—maximizing the chance that our science makes it to patients, not purgatory.